Beam Therapeutics (MEX:BEAM) Long-Term Debt: MXN1,807 Mil (As of Mar. 2026)


MEX:BEAM Beam Therapeutics Inc MEX:BEAM
67 GF Score
Price MXN628.46
GF Value MXN618.99
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Beam Therapeutics Long-Term Debt?

Beam Therapeutics MEX:BEAM 67 Long-Term Debt is MXN1,807 Mil as of Mar. 2026. GuruFocus rates MEX:BEAM with a GF Score™ of 67/100 and a GF Value™ of MXN618.99 (Fairly Valued). The stock has 6 warning signs investors should review.

Beam Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2026 was MXN1,807 Mil.

Beam Therapeutics's quarterly Long-Term Debt stayed the same from Sep. 2025 (MXN0 Mil) to Dec. 2025 (MXN0 Mil) but then increased from Dec. 2025 (MXN0 Mil) to Mar. 2026 (MXN1,807 Mil).

Beam Therapeutics  (MEX:BEAM) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Beam Therapeutics Long-Term Debt Related Terms

Beam Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics Long-Term Debt Chart

Beam Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Beam Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 1,806.75
MEX:BEAM
67GF Score
Beam Therapeutics Inc MEX:BEAM
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of MXN1,807 Mil mean?
Beam Therapeutics (MEX:BEAM) has a Long-Term Debt of MXN1,807 Mil as of Mar. 2026.
Is Beam Therapeutics' Long-Term Debt too high?
Beam Therapeutics' current Long-Term Debt is MXN1,807 Mil. Overall, Beam Therapeutics has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Long-Term Debt compare to ELVN and IDYA?
Beam Therapeutics' Long-Term Debt of MXN1,807 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Beam Therapeutics's current Long-Term Debt is MXN1,807 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Fairly Valued. The stock's GF Value™ is MXN618.99, compared to a current price of MXN628.46 — trading 1.5% above its estimated fair value. The current Long-Term Debt is MXN1,807 Mil. Beam Therapeutics' overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Long-Term Debt is MXN1,807 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of MXN628.46 is trading 1.5% above its estimated GF Value™ of MXN618.99. GuruFocus considers Beam Therapeutics to be Fairly Valued.

Key valuation signals for MEX:BEAM:

  • Long-Term Debt: MXN1,807 Mil
  • GF Value™: MXN618.99 vs. price of MXN628.46 (1.5% above fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
67GF Score

Get the complete analysis for MEX:BEAM

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN628.46
Price
MXN618.99
GF Value